Tolerance of didanosine as enteric-coated capsules versus buffered tablets

AIDS Patient Care and STDs

Volumn 18, Issue 6, 2004, Pages 329-331

  Barreiro, Pablo ^a   Corbatón, Arturo ^a   Núñiz, Marina ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CITRIC ACID; DIDANOSINE; NELFINAVIR; PHOSPHATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; SUCROSE; TENOFOVIR; VIRUS RNA;

ADULT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG TOLERANCE; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; SENSORY NEUROPATHY; TABLET; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DIDANOSINE; DOSAGE FORMS; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 3042683995     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/1087291041444087     Document Type: Letter

References (6)

1. Perry C, Balfour J. Didanosine: An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996;52:928-962.
2. Hartman N, Yarchoan R, Pluda J, et al. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe HIV infection. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 1991;50:278-285.
3. Yarchoan R, Pluda J, Perno C, et al. Antiretroviral therapy of HIV infections: Current strategies and challenges for the future. Blood 1991;78:859-884.
4. Damle B, Kaul S, Behr D, Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablets, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol 2002;42:791-797.
5. Kunches L, Reinhalter N, Marquis A, et al. Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection. J Acquir Immune Defic Syndr 2001;28:150-153.
6. Schrader S, Sharma S, Seekins D, et al. Comparison of HIV RNA suppression produced by triple regimens containing either didanosine enteric-coated or didanosine tablet formulations each administered once daily [Abstract 318]. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 2001.